Cancer Biology & Medicine最新文献

筛选
英文 中文
Advances and challenges in gastric cancer testing: the role of biomarkers. 胃癌检测的进展与挑战:生物标志物的作用。
IF 5.6 2区 医学
Cancer Biology & Medicine Pub Date : 2025-03-24 DOI: 10.20892/j.issn.2095-3941.2024.0386
Yu Sun, Pavitratha Puspanathan, Tony Lim, Dongmei Lin
{"title":"Advances and challenges in gastric cancer testing: the role of biomarkers.","authors":"Yu Sun, Pavitratha Puspanathan, Tony Lim, Dongmei Lin","doi":"10.20892/j.issn.2095-3941.2024.0386","DOIUrl":"10.20892/j.issn.2095-3941.2024.0386","url":null,"abstract":"<p><p>Advances in the identification of molecular biomarkers and the development of targeted therapies have enhanced the prognosis of patients with advanced gastric cancer. Several established biomarkers have been widely integrated into routine clinical diagnostics of gastric cancer to guide personalized treatment. Human epidermal growth factor receptor 2 (HER2) was the first molecular biomarker to be used in gastric cancer with trastuzumab being the first approved targeted therapy for HER2-positive gastric cancer. Programmed death-ligand 1 positivity and microsatellite instability can guide the use of immunotherapies, such as pembrolizumab and nivolumab. More recently, zolbetuximab has been approved for patients with claudin 18.2-positive diseases in some countries. More targeted therapies, including savolitinib for MET-positive patients, are currently under clinical investigation. However, the clinical application of these diagnostic approaches could be hampered by many existing challenges, including invasive and costly sampling methods, variability in immunohistochemistry interpretation, high costs and long turnaround times for next-generation sequencing, the absence of standardized and clinically validated diagnostic cut-off values for some biomarkers, and tumor heterogeneity. Novel testing and analysis techniques, such as artificial intelligence-assisted image analysis and multiplex immunohistochemistry, and emerging therapeutic strategies, including combination therapies that integrate immune checkpoint inhibitors with targeted therapies, offer potential solutions to some of these challenges. This article reviews recent progress in gastric cancer testing, outlines current challenges, and explores future directions for biomarker testing and targeted therapy for gastric cancer.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11976707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer. DB-1310是一种靶向her3的抗体-药物偶联物,在表达HER2和her3的乳腺癌中与曲妥珠单抗具有协同抗肿瘤活性。
IF 5.6 2区 医学
Cancer Biology & Medicine Pub Date : 2025-03-19 DOI: 10.20892/j.issn.2095-3941.2024.0586
Xi Li, Liwen Liang, Zhongyuan Zhu, Haiqing Hua, Yang Qiu
{"title":"DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer.","authors":"Xi Li, Liwen Liang, Zhongyuan Zhu, Haiqing Hua, Yang Qiu","doi":"10.20892/j.issn.2095-3941.2024.0586","DOIUrl":"10.20892/j.issn.2095-3941.2024.0586","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11976708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights into the DNA damage response and tumor drug resistance. DNA损伤反应与肿瘤耐药性的深入研究。
IF 5.6 2区 医学
Cancer Biology & Medicine Pub Date : 2025-03-18 DOI: 10.20892/j.issn.2095-3941.2025.0020
Xiaolu Ma, Zina Cheng, Caixia Guo
{"title":"Insights into the DNA damage response and tumor drug resistance.","authors":"Xiaolu Ma, Zina Cheng, Caixia Guo","doi":"10.20892/j.issn.2095-3941.2025.0020","DOIUrl":"10.20892/j.issn.2095-3941.2025.0020","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11976711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma. 持续的R-DA-EDOCH交替使用高剂量的Ara-C可诱导新诊断的年轻套细胞淋巴瘤患者深度缓解并克服高危因素。
IF 5.6 2区 医学
Cancer Biology & Medicine Pub Date : 2025-03-12 DOI: 10.20892/j.issn.2095-3941.2024.0200
Yi Wang, Yuting Yan, Dandan Shan, Jiawen Chen, Wei Liu, Tingyu Wang, Gang An, Weiwei Sui, Wenyang Huang, Wenjie Xiong, Huimin Liu, Qi Sun, Huijun Wang, Zhijian Xiao, Jianxiang Wang, Lugui Qiu, Dehui Zou, Shuhua Yi
{"title":"Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma.","authors":"Yi Wang, Yuting Yan, Dandan Shan, Jiawen Chen, Wei Liu, Tingyu Wang, Gang An, Weiwei Sui, Wenyang Huang, Wenjie Xiong, Huimin Liu, Qi Sun, Huijun Wang, Zhijian Xiao, Jianxiang Wang, Lugui Qiu, Dehui Zou, Shuhua Yi","doi":"10.20892/j.issn.2095-3941.2024.0200","DOIUrl":"10.20892/j.issn.2095-3941.2024.0200","url":null,"abstract":"<p><strong>Objective: </strong>Our previous studies have indicated potentially higher proliferative activity of tumor cells in Chinese patients with mantle-cell lymphoma (MCL) than those in Western. Given the success and tolerability of R-DA-EDOCH immunochemotherapy in treating aggressive B-cell lymphomas, we designed a prospective, phase 3 trial to explore the efficacy and safety of alternating R-DA-EDOCH/R-DHAP induction therapy for young patients with newly diagnosed MCL. The primary endpoint was the complete remission rate (CRR) at the end of induction (EOI).</p><p><strong>Methods: </strong>A total of 55 patients were enrolled. The CRR at the EOI was 89.1% [95% confidence interval (CI) 78%-96%], and the overall response rate was 98.1% (95% CI 90%-100%). Most patients with bone marrow involvement quickly attained minimal residual disease (MRD) negative status, with a 95.7% rate at the EOI.</p><p><strong>Results: </strong>The 3-year progression-free survival (PFS) and overall survival rates were 66.3% and 83.2%, respectively. No patients discontinued treatment because of adverse events. Univariate analysis identified pathologic morphology and TP53 mutations as risk factors for PFS. However, high tumor proliferative activity and certain cytogenetic abnormalities showed no significant adverse prognostic significance.</p><p><strong>Conclusions: </strong>Intensive therapy based on a high cytarabine dose and continuously administered EDOCH achieved a high MRD-negative rate and provides an optional induction choice for young patients with MCL with high-risk factors.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"22 2","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11899595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in gut microbiota-related treatment strategies for managing colorectal cancer in humans. 与肠道微生物群相关的人类结肠直肠癌治疗策略的进展。
IF 5.6 2区 医学
Cancer Biology & Medicine Pub Date : 2025-03-12 DOI: 10.20892/j.issn.2095-3941.2024.0263
Bhaskar Roy, Kunfeng Cao, Chabungbam Orville Singh, Xiaodong Fang, Huanming Yang, Dong Wei
{"title":"Advances in gut microbiota-related treatment strategies for managing colorectal cancer in humans.","authors":"Bhaskar Roy, Kunfeng Cao, Chabungbam Orville Singh, Xiaodong Fang, Huanming Yang, Dong Wei","doi":"10.20892/j.issn.2095-3941.2024.0263","DOIUrl":"10.20892/j.issn.2095-3941.2024.0263","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a major contributor to global cancer-related mortality with increasing incidence rates in both developed and developing regions. Therefore, CRC presents a significant challenge to global health. The development of innovative tools for enhancing early CRC screening and diagnosis, along with novel treatments and therapies for improved management, remains an urgent necessity. CRC is intricately associated with the gut microbiota, which is integral to food digestion, nutrient generation, drug metabolism, metabolite production, immune enhancement, endocrine regulation, neurogenesis modulation, and the maintenance of physiologic and psychological equilibrium. Dysbiosis or imbalances in the gut microbiome have been implicated in various disorders, including CRC. Emerging evidence highlights the critical role of the gut microbiome in CRC pathogenesis and treatment, which presents potential opportunities for early detection and diagnosis. Despite substantial advances in understanding the relationship between the gut microbiota and CRC, significant challenges persist. Gaining a deeper and more detailed understanding of the interactions between the human microbiota and cancer is essential to fully realize the potential of the microbiota in cancer management. Unlike genetic factors, the gut microbiome is subject to modification, offering a promising avenue for the development of CRC treatments and drug discovery. This review provides an overview of the interactions between the human gut microbiome and CRC, while examining prospects for precision management of CRC.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"22 2","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11899591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism. 缬氨酸通过抑制mTOR的激活和破坏嘧啶代谢来抑制肺癌细胞的增殖。
IF 5.6 2区 医学
Cancer Biology & Medicine Pub Date : 2025-02-24 DOI: 10.20892/j.issn.2095-3941.2024.0385
Lili Yan, Yanfen Liu, Yufei Huang, Xiaoyu Sun, Haiyang Jiang, Jie Gu, Jing Xia, Xueni Sun, Xinbing Sui
{"title":"Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism.","authors":"Lili Yan, Yanfen Liu, Yufei Huang, Xiaoyu Sun, Haiyang Jiang, Jie Gu, Jing Xia, Xueni Sun, Xinbing Sui","doi":"10.20892/j.issn.2095-3941.2024.0385","DOIUrl":"10.20892/j.issn.2095-3941.2024.0385","url":null,"abstract":"<p><strong>Objective: </strong>Erianin has potential anticancer activities, especially against lung cancer. The specific mechanisms underlying the anti-cancer effects, including the molecular targets and signaling pathways in lung cancer, remain poorly understood and necessitate further investigation.</p><p><strong>Methods: </strong>Lung cancer cell viability was evaluated using the CCK-8 assay. Flow cytometry was used to examine the effects of erianin on apoptosis and cell cycle progression. mRNA sequencing and metabolomics analysis were utilized to explore erianin-induced biological changes. Potential targets were identified and validated through molecular docking and Western blot analysis. The roles of mammalian target of rapamycin (mTOR) and carbamoyl-phosphate synthetase/aspartate transcarbamylase/dihydroorotase (CAD) in erianin-induced growth inhibition were studied using gene overexpression/knockdown techniques with uridine and aspartate supplementation confirming pyrimidine metabolism involvement. Additionally, lung cancer-bearing nude mouse models were established to evaluate the anti-lung cancer effects of erianin <i>in vivo</i>.</p><p><strong>Results: </strong>Erianin significantly inhibits the proliferation of lung cancer cells, induces apoptosis, and causes G<sub>2</sub>/M phase cell cycle arrest. Integrative analysis of mRNA sequencing and metabolomics data demonstrated that erianin disrupts pyrimidine metabolism in lung cancer cells. Notably, uridine supplementation mitigated the inhibitory effects of erianin, establishing a connection between pyrimidine metabolism and anticancer activity. Network pharmacology analyses identified mTOR as a key target of erianin. Erianin inhibited mTOR phosphorylation, thereby blocking downstream effectors (S6K and CAD), which are essential regulators of pyrimidine metabolism.</p><p><strong>Conclusions: </strong>Erianin is a promising therapeutic candidate for lung cancer. Erianin likely inhibits lung cancer cell growth by disrupting pyrimidine metabolism by suppressing mTOR activation.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11899589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines. 2024年CSCO晚期非小细胞肺癌指南更新。
IF 5.6 2区 医学
Cancer Biology & Medicine Pub Date : 2025-02-24 DOI: 10.20892/j.issn.2095-3941.2024.0497
Jiale Wang, Tianyu Qiu, Shengxiang Ren
{"title":"Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines.","authors":"Jiale Wang, Tianyu Qiu, Shengxiang Ren","doi":"10.20892/j.issn.2095-3941.2024.0497","DOIUrl":"10.20892/j.issn.2095-3941.2024.0497","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11899588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC. 2024年中国临床肿瘤学会非小细胞肺癌(CSCO NSCLC)指南:早期和局部晚期NSCLC治疗的关键更新
IF 5.6 2区 医学
Cancer Biology & Medicine Pub Date : 2025-02-24 DOI: 10.20892/j.issn.2095-3941.2024.0592
Siyuan Chen, Zhijie Wang, Boyang Sun
{"title":"Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC.","authors":"Siyuan Chen, Zhijie Wang, Boyang Sun","doi":"10.20892/j.issn.2095-3941.2024.0592","DOIUrl":"10.20892/j.issn.2095-3941.2024.0592","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11976710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel BaEVRless-LV packaging system for the production of lentiviral vectors for clinical-grade CAR-NK cell manufacturing. 一种新型的BaEVRless-LV包装系统,用于生产慢病毒载体,用于临床级CAR-NK细胞制造。
IF 5.6 2区 医学
Cancer Biology & Medicine Pub Date : 2025-02-21 DOI: 10.20892/j.issn.2095-3941.2024.0551
Yinyin Zhang, Minghuan Zhang, Mengyuan Li, Lihong Zong, Qian Ye, Wen Lei, Wenhai Deng, Wenbin Qian
{"title":"A novel BaEVRless-LV packaging system for the production of lentiviral vectors for clinical-grade CAR-NK cell manufacturing.","authors":"Yinyin Zhang, Minghuan Zhang, Mengyuan Li, Lihong Zong, Qian Ye, Wen Lei, Wenhai Deng, Wenbin Qian","doi":"10.20892/j.issn.2095-3941.2024.0551","DOIUrl":"10.20892/j.issn.2095-3941.2024.0551","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11899593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved treatment of colorectal liver metastases by early response evaluation and regimen adjustment: a prospective study of clinical functional MR-based modeling. 通过早期反应评估和方案调整改善结直肠肝转移的治疗:基于临床功能磁共振模型的前瞻性研究。
IF 5.6 2区 医学
Cancer Biology & Medicine Pub Date : 2025-02-21 DOI: 10.20892/j.issn.2095-3941.2024.0389
Wenhua Li, Huan Zhang, Zhe Gong, Yue Li, Zhiyu Chen, Xiaodong Zhu, Mingzhu Huang, Zhe Zhang, Chenchen Wang, Lixin Qiu, Qirong Geng, Jinjia Chang, Xiaoying Zhao, Xuedan Sheng, Wen Zhang, Tong Tong, Weijian Guo
{"title":"Improved treatment of colorectal liver metastases by early response evaluation and regimen adjustment: a prospective study of clinical functional MR-based modeling.","authors":"Wenhua Li, Huan Zhang, Zhe Gong, Yue Li, Zhiyu Chen, Xiaodong Zhu, Mingzhu Huang, Zhe Zhang, Chenchen Wang, Lixin Qiu, Qirong Geng, Jinjia Chang, Xiaoying Zhao, Xuedan Sheng, Wen Zhang, Tong Tong, Weijian Guo","doi":"10.20892/j.issn.2095-3941.2024.0389","DOIUrl":"10.20892/j.issn.2095-3941.2024.0389","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to evaluate the feasibility of functional MR in predicting the clinical response to chemotherapy in patients with colorectal liver metastases (CLM).</p><p><strong>Methods: </strong>A total of 196 eligible patients were enrolled in the study between August 2016 and January 2023. Functional MR was performed at baseline and after one cycle of chemotherapy. The diffusion kurtosis radiomic texture features were extracted and a signature model was built using the R package. The initial 100 cases were designated as the training set, the following 48 cases were designated as the validation set, and the final 48 cases were designated as the intervention validation set.</p><p><strong>Results: </strong>Good performance for the response prediction (AUC = 0.818 in the training set and 0.755 in the validation set) was demonstrated. The objective response rates (ORRs) in the high-risk subgroup were significantly lower than the low-risk subgroup in the training and validation sets. Worse progression-free survival and overall survival rates were noted in the high-risk population. In the intervention set 22.9% (11/48) of the chemotherapy regimens for patients were changed in response to the model-predicted results and the ORR reached 77.1% (37/48), which was significantly higher than the training and validation sets [47.97% (71/148); <i>P</i> = 0.000].</p><p><strong>Conclusions: </strong>A functional MR signature effectively predicted the chemotherapy response and long-term survival. The adjustment of the regimen guided by the model significantly improved the ORR.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11899590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信